PPIB and neoplasm: Although the combination of trametinib/dabrafenib has considerably prolonged disease free progression and overall survival for patients with mutant B-RAF melanoma, eventually tumor cells under the restrictive pressure of the drug combination evolve mechanisms of resistance.